List of works by Thomas F. Gajewski

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.

scientific article published on 8 December 2016

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

scientific article (publication date: November 2016)

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

scientific article published oln 16 November 2016

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265).

scientific article published on 4 November 2015

A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab

scientific article published on 01 March 2020

A new paradigm for tumor immune escape: β-catenin-driven immune exclusion

scientific article published on 15 September 2015

A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma.

scientific article published on 3 February 2016

A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma.

scientific article published on 12 July 2009

A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma

scientific article

ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients

scientific article published on 24 January 2020

Abstract IA10: Effective immunotherapy regimens incorporating highly active human STING-activating cyclic dinucleotide derivatives

Agonist anti-4-1BB plus neutralizing anti-CTLA-4 or -PD-L1 synergize to promote tumor regression by rescuing dying dysfunctional CD8+ T cells within the tumor microenvironment

scientific article published on 4 November 2015

Agonistic 4-1bb antibodies in combination with inhibitory antibodies against CTLA-4, PD-L1 or LAG-3 ACT on CD8+ T cells in the tumor microenvironment and synergize to promote regression of established tumors

An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells

scientific article

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.

scientific article published on 30 May 2018

Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA.

scientific article published on 29 February 2016

Back from the dead: TIL apoptosis in cancer immune evasion

scientific article published on 23 January 2018

Beta-catenin does not regulate memory T cell phenotype

scientific article published in May 2010

Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-γ1 phosphorylation

scientific article published on 13 December 2010

Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma.

scientific article published on 6 May 2014

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro

article

CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells

scientific article

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

scientific article

CD40 ligation reverses T cell tolerance in acute myeloid leukemia

scientific article published on 24 April 2013

COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19

scientific article published on 26 July 2020

Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.

scientific article

Cancer and the Microbiome: Influence of the commensal microbiota on cancer, immune responses, and immunotherapy

scientific article published on 27 November 2020

Cancer classification using the Immunoscore: a worldwide task force

scientific article

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

scientific article published on 16 August 2016

Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation

scientific article published on 6 February 2012

Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment

scientific article

Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.

scientific article

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study

scientific article published on 15 July 2014

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

scientific article published on 5 November 2015

Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction

scientific article

Costimulatory and coinhibitory receptors in anti-tumor immunity

scientific article published on May 2009

Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy

scientific article published on 28 February 2006

Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells

article

Defining the critical hurdles in cancer immunotherapy

scientific article published on 14 December 2011

Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes

scientific article published on 01 December 2003

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

scientific article published on 7 May 2015

Direct activation of STING in the tumor microenvironment with synthetic cyclic dinucleotide derivatives leads to potent and systemic tumor-specific immunity

Distinct Graft-Specific TCR Avidity Profiles during Acute Rejection and Tolerance

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial

scientific article published on 18 June 2014

Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics

scientific article published on 4 November 2015

Egr2 targets identify a population of dysfunctional T cells in the tumor microenvironment with immune modulatory properties

scientific article published on 7 November 2013

Egr2 targets identify a population of dysfunctional T cells in the tumor microenvironment with immune modulatory properties.

scientific article published on 6 November 2014

Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy

scientific article published on 30 March 2013

Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy

scientific article published on 24 August 2015

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

scientific article published on 17 June 2019

Evidence implicating the commensal microbiota in shaping anti-tumor immunity in melanoma

article

Exploring the emerging role of the microbiome in cancer immunotherapy

scholarly article by Jessica Fessler et al published 17 April 2019 in Journal for Immunotherapy of Cancer

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

scientific article published on 15 November 2019

Extremely potent immunotherapeutic activity of a STING agonist in the B16 melanoma model in vivo

scientific article published on 7 November 2013

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.

scientific article

Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity

scientific article published on 01 May 2002

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

scientific article

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

scientific article published on 3 June 2013

Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".

scientific article published on 4 July 2012

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

scientific article

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

scientific article published on 30 November 2015

High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions

scientific article published on 13 November 2018

Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting

scientific article published on 29 May 2013

Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection

scientific article published on 01 October 2006

Homeostatic proliferation of naïve CD8+ T cells depends on CD62L/L-selectin-mediated homing to peripheral LN.

scientific article published in November 2009

Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma

scientific article

Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk

scientific article

ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo.

scientific article published on March 2005

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin

scientific article

Immune resistance orchestrated by the tumor microenvironment

scientific article published on October 2006

Immune suppression in the tumor microenvironment

scientific article

Immune surveillance is thwarted by tumor-cell intrinsic beta-catenin signaling.

scientific article published on 4 November 2015

Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma

scientific article

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

scientific article published on 15 January 2018

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.

scientific article published in December 2016

Immunotherapy with a sting

scientific article published on 01 August 2020

Induction of cytotoxic granules in human memory CD8+ T cell subsets requires cell cycle progression.

scientific article

Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy

article

Innate immune sensing of a growing tumor in vivo occurs via the host sting pathway and involves mitochondrial DNA transfer from cancer cells to DCs.

scientific article published on 7 November 2013

Innate immune signaling and regulation in cancer immunotherapy

scientific article published on 16 December 2016

Innovations and challenges in melanoma: summary statement from the first Cambridge conference

scientific article published on 01 April 2006

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

scientific article published on 01 April 2020

Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy

scientific article

Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity

scientific article

LAG-3 and 4-1BB identify dysfunctional antigen-specific T cells in the tumor microenvironment and combinatorial LAG-3/4-1BB targeting gives synergistic tumor control.

scientific article published on 4 November 2015

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

scientific article published on 8 December 2015

Lymphatic vessels regulate immune microenvironments in human and murine melanoma

scientific article published on 15 August 2016

MYC - a thorn in the side of cancer immunity

scientific article published on 26 April 2016

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment

scientific article

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

scientific article

Melanoma-intrinsic β-catenin signaling prevents T cell infiltration and anti-tumor immunity

scientific article published on 6 November 2014

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

scientific article published on 11 May 2015

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma

scientific article

Molecular regulation of T-cell anergy

scientific article

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

scientific article published on 01 August 2018

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

scientific article published on September 2017

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model

scientific article published on 05 May 2009

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)

scientific article published on 21 July 2018

Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)

scientific article published on 07 September 2020

Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)

scientific article published on 22 July 2019

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma

scientific article published on 20 March 2019

Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.

scientific article

Phase I/II trial of tremelimumab in patients with metastatic melanoma

article

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

scientific article published on 18 February 2015

Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma

scientific article

Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma

scientific article published on 15 November 2012

Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers

scientific article published on 4 November 2015

Protein kinase Ctheta focusing at the cSMAC is a consequence rather than cause of TCR signaling and is dependent on the MEK/ERK pathway.

scientific article published in May 2009

Rational combinations of immunotherapeutics that target discrete pathways

scientific article

Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma

scientific article published on 05 December 2016

Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM).

scientific article published in October 2017

Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics.

scientific article published on September 2007

Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer ⬇️

scientific article published on 12 May 2011

SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery

scientific article

STING pathway agonism as a cancer therapeutic

scientific article published on 01 July 2019

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma

scientific article published on 07 April 2017

Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma

scientific article published on 08 November 2019

Sensitive detection and quantification of SARS-CoV-2 in saliva

scientific article published on 07 December 2020

Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial

scientific article published on 21 June 2016

T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha

scientific article published on 8 October 2006

T cell development and function in CrkL‐deficient mice ⬇️

scientific article published on October 1, 2003

Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases

scientific article published on August 2007

The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment.

scientific article published on 23 January 2017

The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer

scientific article published on 01 February 2009

The STING pathway and the T cell-inflamed tumor microenvironment

scientific article

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

scientific article

The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.

scientific article

The composition of the microbiota modulates allograft rejection

scientific article published on 20 June 2016

The host STING pathway at the interface of cancer and immunity

scientific article published on July 2016

The immune score as a new possible approach for the classification of cancer

scientific article published on 3 January 2012

The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies.

scientific article

Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment

scientific article published on 7 November 2013

Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo

scientific article

Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy

scientific article

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

scientific article published on 11 October 2017

Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells

scientific article published on 30 January 2020

Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites

Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy

scientific article

Tumor-intrinsic oncogene pathways mediating immune avoidance

scientific article

Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy

scientific article published on 11 February 2016

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAFV600- mutated melanoma (BRIM7).

scientific article published on 6 May 2014

Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells

scientific article published on 26 December 2007

WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia

scientific article published on 11 January 2018

Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011.

scientific article published on 28 May 2012

Paulina is supported by:

About Paulina

Help